PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
187.54%
Cash & equivalents growing 187.54% while AXSM's declined -200.00%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
187.23%
Higher Cash + Short-Term Investments Growth compared to AXSM's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
168.93%
Below half of AXSM's -4.59%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-20.60%
Both AXSM and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.19%
Below half of AXSM's -6242.22%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
164.96%
Below half of AXSM's -100.00%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-45.35%
Less than half of AXSM's -100.00%. David Dodd sees a more disciplined AP approach or lower volume.
-33.08%
Less than half of AXSM's -100.00%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
43.64%
Below half of AXSM's -100.00%. Michael Burry suspects a big gap in pre-sales traction.
-68.51%
50-75% of AXSM's -100.00%. Bruce Berkowitz notes a more controlled liability line.
-61.96%
50-75% of AXSM's -100.00%. Bruce Berkowitz notes the firm keeps current liabilities growth relatively low.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-61.96%
50-75% of AXSM's -100.00%. Bruce Berkowitz notes a lower yoy liability increase.
19.13%
Less than half of AXSM's -100.00%. David Dodd sees fewer share issuances vs. competitor.
-3.37%
Below half AXSM's 100.00%. Michael Burry suspects major net losses or high dividends vs. competitor.
-26.34%
Higher AOCI Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
955.36%
Higher Total Stockholders' Equity Growth compared to AXSM's zero value, indicating better performance.
164.96%
Below half AXSM's -214.94%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-33.08%
Less than half of AXSM's -100.00%. David Dodd sees less overall debt expansion vs. competitor.
-197.28%
Less than half of AXSM's 40.36%. David Dodd sees better deleveraging or stronger cash buildup than competitor.